• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.

作者信息

Furuhashi Masato, Moniwa Norihito, Takizawa Hideki, Ura Nobuyuki, Shimamoto Kazuaki

机构信息

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.

Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan.

出版信息

Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.

DOI:10.1038/s41440-020-0478-1
PMID:32433641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7237878/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7fe/7237878/97d95b3ec541/41440_2020_478_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7fe/7237878/97d95b3ec541/41440_2020_478_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7fe/7237878/97d95b3ec541/41440_2020_478_Fig1_HTML.jpg

相似文献

1
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎中2019冠状病毒感染及肺损伤的潜在差异影响
Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.
2
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
3
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
4
The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.冠状病毒感染中的肾素-血管紧张素-醛固酮系统——大流行期间的当前思考
J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1717-1719. doi: 10.1053/j.jvca.2020.04.010. Epub 2020 Apr 16.
5
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
6
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
7
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
8
Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂与 COVID-19 合并高血压患者的死亡率降低相关。
Scott Med J. 2020 Nov;65(4):123-126. doi: 10.1177/0036933020949219. Epub 2020 Aug 17.
9
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.新型冠状病毒相关肺损伤中经典肾素-血管紧张素系统与其拮抗系统之间的失衡。
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
10
Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.新型冠状病毒肺炎患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用、胃肠道症状与死亡率之间的关联
Gastroenterology. 2020 Sep;159(3):1170-1172.e1. doi: 10.1053/j.gastro.2020.05.034. Epub 2020 May 16.

引用本文的文献

1
Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2.SARS-CoV-2 变异株 Spike 蛋白下调 ACE2 的能力差异。
Int J Mol Sci. 2024 Jan 22;25(2):1353. doi: 10.3390/ijms25021353.
2
Unraveling the Underlying Molecular Mechanism of 'Silent Hypoxia' in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway.揭示新冠病毒感染患者“沉默性低氧血症”的潜在分子机制表明，血管紧张素II对AT1R-缺氧诱导因子信号通路的调节起着核心作用。
J Clin Med. 2023 Mar 22;12(6):2445. doi: 10.3390/jcm12062445.
3
Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis.

本文引用的文献

1
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
2
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
3
尸检肺、肾和肝组织样本中 SARS-CoV-2 感染的证据，揭示了 COVID-19 发病机制中涉及的细胞靶标。
Arch Virol. 2023 Feb 26;168(3):96. doi: 10.1007/s00705-023-05711-y.
4
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells.细胞因子风暴和细菌感染在 COVID-19 患者中的关键作用：间充质干细胞的治疗潜力。
Inflammopharmacology. 2023 Feb;31(1):171-206. doi: 10.1007/s10787-022-01132-6. Epub 2023 Jan 4.
5
The relationship between chronic immune response and neurodegenerative damage in long COVID-19.长新冠中慢性免疫反应与神经退行性损伤的关系。
Front Immunol. 2022 Dec 16;13:1039427. doi: 10.3389/fimmu.2022.1039427. eCollection 2022.
6
An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.血管紧张素转换酶2的结构/功能、多态性及其在2019冠状病毒病病理生理学中的双重性质的最新进展：对与严重急性呼吸综合征冠状病毒感染相关的血管和凝血疾病的影响。
Front Microbiol. 2022 Nov 28;13:1042200. doi: 10.3389/fmicb.2022.1042200. eCollection 2022.
7
Overlapping of Pulmonary Fibrosis of Postacute COVID-19 Syndrome and Tuberculosis in the Helminth Coinfection Setting in Sub-Saharan Africa.撒哈拉以南非洲地区蠕虫合并感染情况下，急性COVID-19后综合征肺纤维化与肺结核的重叠情况
Trop Med Infect Dis. 2022 Jul 30;7(8):157. doi: 10.3390/tropicalmed7080157.
8
Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?与 SARS-CoV-2 感染相关的脑血管并发症：它是如何发生的，应该如何治疗？
Biomed Pharmacother. 2022 Oct;154:113534. doi: 10.1016/j.biopha.2022.113534. Epub 2022 Aug 17.
9
The Associations between Cytokine Levels, Kidney and Heart Function Biomarkers, and Expression Levels of Angiotensin-Converting Enzyme-2 and Neuropilin-1 in COVID-19 Patients.新冠病毒肺炎患者细胞因子水平、肾脏和心脏功能生物标志物以及血管紧张素转换酶2和神经纤毛蛋白1表达水平之间的关联
Vaccines (Basel). 2022 Jun 29;10(7):1045. doi: 10.3390/vaccines10071045.
10
Obesity or increased body mass index and the risk of severe outcomes in patients with COVID-19: A protocol for systematic review and meta-analysis.肥胖或体重指数增加与 COVID-19 患者严重结局风险的关系：系统评价和荟萃分析方案。
Medicine (Baltimore). 2022 Jan 7;101(1):e28499. doi: 10.1097/MD.0000000000028499.
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
高血压、肾素-血管紧张素系统与下呼吸道感染和肺损伤风险：对 COVID-19 的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1688-1699. doi: 10.1093/cvr/cvaa097.
4
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
5
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.2019冠状病毒病（COVID-19）感染与肾素-血管紧张素系统阻滞剂
JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282.
6
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.血管紧张素转化酶抑制剂改善合并高血压的 COVID-19 患者的临床结局。
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
7
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
8
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
9
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
10
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.